BACKGROUND: Hemorrhagic shock and pneumonectomy causes an acute increase in pulmonary vascular resistance (PVR). The increase in PVR and right ventricular (RV) afterload leads to acute RV failure, thus reducing left ventricular (LV) preload and output. Inhaled nitric oxide (iNO) lowers PVR by relaxing pulmonary arterial smooth muscle without remarkable systemic vascular effects. We hypothesized that with hemorrhagic shock and pneumonectomy, iNO can be used to decrease PVR and mitigate right heart failure.
A lthough pneumonectomy in the setting of trauma is a rare occurrence, in the presence of pulmonary hilar vascular or extensive main stem bronchial injury, pneumonectomy may be the only option. Of the few case series in the literature demonstrating outcomes of these patients, mortality associated with trauma pneumonectomy has been reported to range from 5% to 100%. [1] [2] [3] [4] Moreover, when pneumonectomy is performed on the background of hemorrhagic shock, the mortality rate is even higher than the mortality rate for pneumonectomy in the setting of isolated bronchial injury. 1 Overall, the high mortality rates have been attributed to right heart failure. [1] [2] [3] [4] Right heart failure after combined hemorrhagic shock and pneumonectomy occurs secondary to an acute increase in pulmonary vascular resistance (PVR). 2, 4 In animal studies, the increase in PVR seen in pneumonectomy and hemorrhagic shock models has been shown to be greater than the additive effects of each of these situations on their own and irreversible. 4 Additionally, pneumonectomy and resuscitation have the potential to cause acute lung injury. 2 This can lead to alveolar hypoxia, a major contributor to pulmonary vasoconstriction and increase in PVR. 2 Ultimately, these risk factors lead to an increase in right ventricular (RV) afterload and a dysfunctional scenario of which compensatory mechanisms are exceeded, resulting in RV failure, decreased cardiac index, systemic hypoperfusion, tissue hypoxia, and death. An effective mechanism for mitigating this problem would include a treatment focused at the source of the increase in PVR, specifically, selective vasodilation of the pulmonary vasculature.
Inhaled nitric oxide (iNO) has been shown to be a selective vasodilator of pulmonary vascular smooth muscle, with minimal or no hemodynamic systemic effects. 5, 6 The reduction in pulmonary vascular tone and consequently PVR leads to decreased pulmonary arterial pressure and ultimately decreased RV afterload, which mechanistically decreases the workload of the right ventricle and has the potential to prevent right heart failure. 6 These beneficial properties of iNO have been used to induce vasodilation in primary pulmonary hypertension, ARDS and secondary pulmonary hypertension due to congenital heart disease. 7 In a nonrandomized study of patients with acute right heart failure, iNO was shown to increase cardiac output, stroke volume, and mixed venous oxygen saturation, thereby improving hemodynamic parameters, and although not directly measured, has been related to improving RV dysfunction. 5 Although sparse, the few case studies of the use of iNO in hemorrhagic shock patients requiring trauma pneumonectomy have reported improved cardiac output, reduced pulmonary artery pressures, and ultimately improved survival. 7, 8 However, the impact of iNO to mitigate right heart failure in the presence of hemorrhagic shock and trauma pneumonectomy has not been systematically or directly studied. With this in mind, the purpose of this study was to test the hypothesis that iNO could be used to decrease PVR, unload the right ventricle, and attenuate alterations in right heart function, thereby reduce right heart failure in an animal model of hemorrhagic shock and trauma pneumonectomy.
MATERIALS AND METHODS
All methods were approved by the Temple University animal care and use committee in accordance with National Institutes of Health guidelines. Animal Preparation: Sheep (n = 19; weight: 23.7 ± 0.71 kg) were anesthetized with intramuscular (IM) injections of buprenorphine hydrochloride (0.005 mg/kg) and ketamine/xylazine (20/2 mg/kg), restrained in the supine position, intubated (8.0 mm), immediately instrumented with electrocardiogram leads, pulse oximetry, and an orogastic tube, and placed on lung protective ventilatory support (Servo 300; Siemens, Solna, Sweden) initiated with pressure-controlled (peak inspiratory pressure = 18 cm H 2 0, positive end expiratory pressure = 8 cm H 2 O), synchronized intermittent mechanical ventilation at a rate of 12 breaths/min with heated and humidified FIO 2 (0.40-0.60) titrated to SpO 2 target of > 90%. Bilateral peripheral leg veins were isolated and cannulated for administration of anesthesia (guaifenesin/ketamine/xylazine at 50/2/0.1 mg/mL; 0.25-2.5 mL/kg per hour), maintenance fluids, and autologous blood. The right carotid artery was cannulated (8 Fr) for continuous blood pressure monitoring and serial sampling of arterial blood chemistry. The left femoral artery (8 Fr) and internal jugular vein (16 Fr) were cannulated for blood withdrawal. The right external jugular vein was cannulated with a thermodilution catheter (7.5 Fr) that was advanced into the pulmonary artery under transduced pressure guidance for continuous monitoring of pulmonary pressures and serial measurement of mixed venous blood chemistry and cardiac output. All sheep were placed on a temperature controlled water-circulating pad and under a warming blanket for temperature support as continuously measured by rectal probe.
After baseline measurements (blood pressure, heart rate, pulmonary artery pressures, cardiac output, systemic arterial pressures, ventilator settings, arterial and venous blood chemistries), a lung protective strategy was supported by changing the ventilator mode to time-cycled, pressure-limited (plateau pressure < 30 cm H 2 0), tidal volume-monitored ventilation (~6 mL/kg), and a median sternotomy was performed. As previously described by Cryer et al., 4 the left pulmonary hilum was isolated by gentle positioning of umbilical tape to be used subsequently during the resuscitation phase for ligation as an experimental hemodynamic surrogate of pneumonectomy, and the chest was covered with plastic wrap to minimize temperature and evaporative water loss. Animals were given warm lactated Ringer's (10 mL/kg) to support prehilar manipulation of mean arterial pressure (MAP) and allowed to stabilize for 15 to 20 minutes. Then, previously described baseline measurements were repeated and echocardiography was performed (Zonare z. one ultra-Ultrasound system; 10-3 probe; Zonare Medical Systems, CA). During echocardiography, the animals were randomized to receive placebo (nitrogen; n = 9) or study gas (iNO at 20 ppm; n = 9) delivered just proximal to the inspiratory wyre by the modified iNOmax DS IR delivery system for blinded studies (Ikaria/Mallincrodkt; software version 1.05). Only one member of the study team knew the randomization result; this member was responsible for initiating the placebo or study gas.
The surgical table was elevated to the highest point, transducers were rezeroed and hemorrhagic shock was then created by passive blood flow from the left femoral artery and internal jugular vein into blood collection bags (JorVet, Jorgensen Laboratories, Inc. Loveland, CO) positioned 114 cm below the animal until a target of 50% of baseline systemic MAP was reached and sustained for 5 minutes. Baseline measurements were then repeated. Within 15 minutes of hemorrhagic shock, the resuscitation phase was initiated. Resuscitation consisted of simultaneous ligation of the left pulmonary hilum, infusion of withdrawn blood and initiation of placebo or iNO study gas. To account for single lung ventilation, lung protective ventilation was maintained by monitoring tidal volume via pneumotachography and end-tidal carbon dioxide (NICO CO 2 monitor; Philips-Respironics, Wallingford, CT), reducing inspiratory pressure-support thus tidal volume by 33% (plateau pressure < 30 cm H 2 0), increasing frequency to prevent hypercapnea (PaCO 2 ≤ 60 mm Hg), and titrating FIO 2 to maintain SpO 2 > 90%. Warm lactated Ringer's solution was infused as needed after completion of blood infusion, to return MAP to baseline. In addition to continuous monitoring of vascular pressures, pulse oximetry, and ECG, blood chemistry and cardiac function were serially measured immediately, 30 minutes, then hourly postresuscitation to 4 hours postinjury or until death.
PVR was calculated from mean pulmonary arterial pressure-pulmonary capillary wedge pressure/cardiac output. 9 All echocardiographic analyses were performed in a blinded manner following the American Society of Echocardiography guidelines. Cardiac function was assessed using eccentricity index as an indication of RV pressure overload, RV dP/dT and left ventricular (LV) ejection fraction as a measure of RVand LV systolic function, respectively, and RVand LV fractional area of change (FAC) as an indicator of respective global ventricular function.
Eccentricity index is a measurement of RV pressure versus volume overload that is based on interventricular septum movement. 10, 11 Two measurements of the left ventricle are taken, one perpendicular to the septum and one parallel to the septum. 11 The ratio of these measurements is taken at end systole and end diastole. In a normal patient, the ratio is 1. If RV volume overload is present, the ratio at end systole is 1, but is >1 at end diastole. If RV pressure overload is present, this ratio will be >1 at both end systole and end diastole. RV FAC is a measure of global RV function that has been correlated to RV ejection fraction using MRI. 10 RV FAC is calculated as (RV end diastole area − RV end systolic area) / RVend diastole area Â 100.
11 This is measured by tracing the RV endocardium in systole and diastole in an apical four chamber view in the following order: from the annulus, the free wall to the apex, back to the annulus along the intraventricular septum. 10 A similar measurement is made of the LV cavity. A FAC less than 35% is indicative of systolic dysfunction. 10 Data and statistical analyses were performed using Microsoft EXCEL and Graph Pad PRISM. Physiologic variables were evaluated by multifactorial analysis of variance for time and treatment groups with repeated measures on time. Treatment group means were compared vertically using the Dunn-Bonferroni procedure and horizontally to their respective baseline and last injury value using linear contrast. Data are presented as mean ± SEM and significance was accepted at the p < 0.05 level.
RESULTS
As shown in Table 1 , there were no significant group differences in body weight, baseline systemic or pulmonary arterial pressures, hematocrit, hemoglobin or blood volume withdrawn to achieve 50% MAP. After instrumentation and initiation of study gas, two animals died before the 4-hour endpoint. Both animals were in the placebo group. One animal died immediately after ligation of the pulmonary hilum in which there was immediate and extensive RV dilation and cardiac arrhythmia. This animal was excluded from complete statistical analysis. The other animal died from systemic hypotension and arrhythmia at the 2-hour timepoint. All animals in the iNO-treated group survived to 4 hours. As shown in Figures 1-4 and Table 2 , respectively, there were no significant intergroup differences in baseline values for PVR, any measure of cardiac function, shunt, lactate, SvO 2, PaO 2 , or PaCO 2 .
Upon initiation of the resuscitation phase, PVR ( Fig. 1 ) increased significantly in all animals. In the placebo group, PVR remained elevated from baseline over time. In the iNO group, PVR decreased back toward baseline over time. As shown in Table 2 , shunt and lactate increased significantly, SvO 2 and PaO 2 decreased significantly from baseline initially with the resuscitation phase in both groups. Over time and by 4 hours, with placebo, shunt remained elevated relative to baseline, lactate continued to increase, and PaO 2 and SvO 2 , while increasing significantly from the initial resuscitation phase, remained significantly lower than baseline, and PaCO 2 was greater than baseline, suggestive of impairment in gas exchange and tissue oxygenation over time. With iNO, shunt, SvO 2 and PaO 2 improved, and lactate stabilized, reflecting improved tissues oxygenation as compared with placebo-treated animals.
Cardiac function profile is shown in Figures 2-4 . During the initial resuscitation phase, both placebo-treated and iNOtreated groups demonstrated an increase in eccentricity index at end systole ( Fig. 2) and diastole (not shown), reflective of RV pressure overload. This increase was significantly less in the animals treated with iNO. In the placebo group, the eccentricity index at end systole and diastole continued to increase over time, consistent with a continued increase in RV pressure overload. In contrast, the iNO-treated group demonstrated a return to baseline values within 2 to 3 hours postresuscitation, reflective of return to normal RV pressure loading conditions.
With respect to systolic contractile function, RV dP/dt (Fig. 3, B) decreased significantly initially postresuscitation in both groups, continued to decrease in the placebo-treated animals, and returned to baseline within 2 hrs in animals treated with iNO, reflective of preserved RV contractility. There were significant group differences in bilateral ventricular contractile function as reflected by RV and LV FAC, measurements of global ventricular systolic function. As shown in Figure 3 , D and Figure 4 , B, respectively, both RV and LV FAC were significantly lower in animals treated with placebo gas as compared with iNO. In addition, while continuing to decrease over time in placebo-treated animals suggesting continual impairment of function, RV and LV FAC remained relatively stable in the iNO-treated animals. As shown in Figure 4 , C, the group difference in LV function was further demonstrated by the significantly lower and continual decrease in LV ejection fraction over time in animals treated with placebo gas in contrast to the relative stability of this parameter in animals treated with iNO.
DISCUSSION
This study demonstrates that iNO mitigated the increase in PVR, thus decreasing RVafterload and risk of RV failure after combined hemorrhage and pneumonectomy in the sheep. Our animal model, similar to the pig model previously reported by Cryer et al. 4 simulated the clinical situation of patients who have central hilar injuries causing hemorrhagic shock and who require pneumonectomy for control. Upon ligation, with the removal of one of the two parallel circuits of the pulmonary circulation, there was an acute and robust increase in PVR in both groups of animals. Cardiac instability, including RV dilation, and hemodynamic compromise was observed as previously reported in both animal and humans. [1] [2] [3] [4] 7, 8 In our study, animals treated with placebo gas demonstrated progressive right heart failure as has been demonstrated in humans with hemorrhagic shock and trauma pneumonectomy 3 ; whereas, animals treated with iNO demonstrated the return of elevated PVR back to baseline and preserved RV function.
The return of PVR toward baseline supports the notion that iNO was effectively delivered to the alveolar-capillary membrane to diffuse into the pulmonary smooth muscle cells, activate soluble guanylate cyclase to convert guanosine triphosphate to cylcin guanosine monophosphate thereby increasing intracellular concentrations of cylcin guanosine monophosphate thus facilitating pulmonary vascular smooth muscle relaxation and decrease in PVR. Animals that received iNO had less RV pressure overload (eccentricity index), preserved RV systolic function (RV dp/dt, RV FAC), and preserved LV function (LV EF, LV FAC). Functionally, an interpretation of this finding is that this translated to preserved tissue oxygenation, as demonstrated by the stabilized lactate values and the return of mixed venous oxygen saturation to baseline values. Preservation of RV function and tissue oxygenation seen with iNO in the present study is consistent with that previously demonstrated in humans with acute right heart failure. In this regard, patients in acute right heart failure treated with iNO were reported to respond with a decrease in Figure 2 . Eccentricity Index (A) Representative 2D short axis echocardiographic images of the LV in diastole and systole at 4 hours postresuscitation. The placebo images in diastole and systole (top row) shows deformation of the septal wall versus the iNO-treated animal who has maintained a normal cardiac dimensional ratio (bottom row). (B) The mean eccentricity index (EI) systole (ratio) at baseline, 1, 2, 3, and 4 hours postresuscitation in the (small dot) placebo-treated (n = 9) and (filled square) iNO-treated (n = 9) groups. Data shown as mean ± SEM (*p < 0.05 vs. baseline; #p < 0.05 vs. group).
PVR, pulmonary pressures, increased cardiac output, and ultimately improved tissue perfusion. 5 Several case studies suggest the salutatory effect of iNO on survival after hemorrhagic shock and pneumonectomy. 7, 8 One report described survival after pneumonectomy subsequent to bilateral blunt thoracic injury in which iNO was initiated postoperatively and maintained for 4 days. 8 Another case study reported a 24-year-old patient with a right pulmonary artery injury who received pneumonectomy with initial worsened RV function, who was then treated with iNO experienced reduced pulmonary artery pressures, improved cardiac output, and ultimately survived. 7 In contrast, in animals that received placebo gas (nitrogen), PVR remained elevated which was associated with worse RV function than animals treated with iNO. The placebo animals experienced continued RV pressure overload, decreased global RV systolic function, abnormal motion of the interventricular septum, and ultimately reduced LV EF. This translated to poorer tissue oxygenation, as demonstrated by the blood lactate levels, which remained elevated in these animals and the persistently low mixed venous oxygen saturation. The impaired right heart function seen in the placebo animals is consistent with current theories that increased RV afterload (via increased RV end diastolic volume) ultimately decreased RV ejection fraction, 4, 5 leads to decreased LV end diastolic volume (preload) and ultimately decreased cardiac output. 5 Additionally, RV afterload in this scenario may be increased due to the combination pulmonary vasoconstriction, decreased vascular compliance, and microvascular plugging. 4 This is likely exacerbated by hemorrhagic shock, in which thromboxane release and leukostasis have the potential to interfere with vascular recruitment, leading to vasoconstriction and plugging that further reduces the ability of the RV to compensate, ultimately leading to RV failure. 4 These vascular effects also have the potential to lead to pulmonary edema, precipitating worsening hypoxemia and potentially worsening pulmonary hypertension. 2 This vicious cycle of hypoxemia and pulmonary hypertension leading to RV failure contributes to the demise of these patients because the RV is not able to compensate for the vast increase in PVR.
Our data suggest that iNO is able to selectively vasodilate the pulmonary vasculature, thus decreasing PVR in the setting of hemorrhagic shock and pneumonectomy. This decrease in PVR leads to reduction in RV afterload and preserved RV and LV function. Ultimately, this yields improved tissue oxygenation and potentially survival, in cases when the right heart struggles to compensate in the face of increased afterload. There are several unique strengths of this study. In contrast to previous preclinical studies, we chose to initiate iNO treatment simultaneous with surgical and volume resuscitation. In this regard, our study offers insight to the potential prophylactic application of iNO in the setting of hemorrhagic shock and pneumonectomy. In addition, in an attempt to minimize confounding variables which could impact interpretation, we chose to restrict rescue management to surgical resection, return of autologous blood, and iNO rather than to other additional support of hemodynamic and metabolic status with vasopressors and buffers. Some limitations of the present study should be noted. We recognize that in comparison to massive hilar hemorrhage, our method of hemorrhage from central and peripheral vessels does not present the same clinical challenges with respect to surgical, vascular control, and blood collection for autotransfusion. Based on our interest in the immediate hemorrhagic shock and pneumonectomy resuscitation period, we chose a 4-hour study window as previously described. 4 As such, from this observation period, we can speak only to the short-term benefits of iNO. Nonetheless, our degree of hemorrhage, study period, and alterations in lactate levels paralleled the acuity and intensity experienced by our clinical trauma team and lends insight to the salutatory rescue potential of this approach. Other potential considerations are related to echocardiography. Whereas all measurements were performed by experienced sonographers, they were performed with the open-chest approach which may limit translation to the clinical experience. We recognize that certain echocardiography measurements are loaddependent, and that loading conditions are likely to change over time in a study of this nature. With this in mind, given that both groups were managed in the same way apart from the study gas, we submit that this would impact each group comparably. By nature, there is an element of subjectivity in echocardiogram analyses which may potentially lead to variations in interpretation. This variation was minimized by having all echocardiograms evaluated by the same skilled sonographer. As such, we believe that this is not a likely source of bias in our study.
Summarily, these data provide strong evidence that iNO can be a useful treatment to decrease PVR and reduce RV afterload. Within this context, this study suggests that iNO can be a useful clinical adjunct to mitigate right heart failure and potentially improve survival in the face of hemorrhagic shock when pneumonectomy is required. Further research is warranted to determine iNO management strategies (i.e., dose, duration, weaning; longer durations of shock, with hilar hemorrhage) in this patient population. AUTHORSHIP L.O.S. and M.R.W. were responsible for overall experimental design and were directly involved with study implementation, data collection/analysis, and interpretation, and article development. A.L.L. was involved in study implementation, data collection/analysis and interpretation and article development. L.A.P., J.W., T.E.S., M.W., and R.M.B. were involved in study implementation, data collection/analysis/interpretation and article review. A.G., A.P., and T.S. were involved with review of results and interpretation with specific attention to clinical translation.
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DISCUSSION
Dr. James V. O'Connor (Baltimore, Maryland): Dr. Lubitz, that was a very nice presentation and thank you for getting the manuscript to me in a timely fashion.
Injuries requiring pneumonectomy are among the most challenging to successfully manage. They are rare, even at busy trauma centers, which accounts for the few small series in the literature.
As you mentioned, the mortality ranges anywhere from 50% to 100%. Contrast this to a 5 percent operative mortality for an elective pneumonectomy for malignancy.
Multiple reports have noted that intraoperative mortality following traumatic pneumonectomy results from uncontrollable hemorrhage and/or acute right heart failure, while right heart failure alone tends to account for post-operative mortality.
It was postulated that the rapid increase in pulmonary vascular resistance results in right ventricular dysfunction. This was elegantly confirmed in an animal model by Dr. Cryer demonstrating the combination of hemorrhagic shock and pneumonectomy resulted in significantly high pulmonary vascular resistance than with either hemorrhagic shock or pneumonectomy alone.
In the shock plus pneumonectomy group pulmonary vascular resistance, at four hours, had increased a staggering 500% over baseline. Therefore, if the main determinant of acute right heart failure is the rapid increase in pulmonary vascular resistance, then strategies to lower it are clearly essential.
Inhaled nitric oxide is an attractive option. It is a selective pulmonary vasodilator with little or no systemic effect as it is rapidly inactivated by hemoglobin.
In this blinded, randomized, controlled study the authors have postulated that inhaled nitric oxide would decrease pulmonary vascular resistance, thereby improving right ventricular function in sheep subjected to a combination of hemorrhagic shock and pneumonectomy. In addition to standard hemodynamic monitoring they employed echocardiography to assess ventricular function.
While I believe they have confirmed their hypothesis, I have a few questions regarding the study design and its clinical implications.
In your model, hilar isolation was obtained prior to instituting controlled shock which was accomplished by removing blood from peripheral vessels, not from intrathoracic hemorrhage. Within 15 minutes resuscitation hilar vessel ligation was performed.
In the clinical setting, hemorrhage from hilar vessels is anything but controlled, and obtaining hilar isolation typically takes longer than 15 minutes and generally in less than an ideal operative field. So then how does the model reflect the clinical reality? And that brings me to some clinical applications.
Has this study changed your clinical practice? Specifically, have you started inhaled nitric oxide immediately in the operating room? And what, if any, additional management strategies do you employ?
Although echocardiography is an incredibly valuable and sophisticated modality it only gives a momentary assessment of cardiac function. In addition to echocardiography do you use pulmonary artery catheters to guide additional therapy such as inotropic support?
The last question: inhaled nitric oxide is expensive and in an era of cost containment do you use any less-costly but equally effective measures such as epoprostenol?
I congratulate you and your colleagues for furthering our understanding of the management of this formidable injury and thank the Association for the opportunity to discuss this paper.
Dr. Juan Asensio (Omaha, Nebraska): This is a very nice study. I'd like to congratulate the authors. Obviously, not removing the lung is totally different than in reality. I have some questions.
How much of the shed blood was reinfused and how rapidly? We know that right ventricular failure occurs directly as the amount or the rapidity with which some of the blood is infused.
We also, of course, did not see the use of the Swan-Ganz catheter and I would suggest that that would increase the validity of the study by being able to measure the right ventricular stroke work index.
You talked about thromboxane. It would have been good to biopsy the contralateral lung to take a look a stasis.
As of now, I'd like to congratulate Dr. Spain and the committee for including very nice operative work.
And for the younger people I am glad that Dr. Cryer's study was cited. It is old and that proves to the younger surgeons here that just because the data is old it is not invalid and that is a superbly elegant study.
Thank you. Dr. Juan C. Duchesne (New Orleans, Louisiana): Dr. Lubitz, nice job. I really liked the ultrasound pictures that you demonstrated in your slides because that's a clear visual representation of the impact on pulmonary artery when you have that increased, dramatic increase in volume with dilatation and shift in interventricular septum. This is a contributor of what I call the "double hit."
You are going to have that shock state-and that's the adaptation phase where the patient will benefit from nitric oxide to basically help ameliorate the pulmonary artery resistance. In doing so, the pulmonary pipe system will open up and allow more volume to flow with less resistance a big factor that will ameliorate the deleterious impact of interventricular septum deviation. I see the role of nitric oxide there.
But once the patient arrives to the ICU in the long-term my concern is once your pulmonary parenchyma network of basically volume overload alveoli you're going to have long standing severe vasoconstriction. And that's my question to you. What is the role of nitric oxide in the long-term?
I remember cases of pneumonectomies back when I was a fellow in Charity where we were not able to wean off the nitric oxide and the bill was going crazy by the second while on nitric oxide. So I just want to know what is your perspective on this long-term pulmonary physiology adaptation?
Dr. David J. Dries (Saint Paul, Minnesota): This is a very elegant physiologic study and I congratulate the authors. As this model will cause an inherent increase in right ventricular outflow impedance, I suggest that the authors, instead of simply returning removed blood, should titrate fluid administration, possibly with echocardiography. A second important consideration in this model is titration of tidal volume and airway pressure as both of these factors will also contribute to increased right ventricular outflow impedance. In particular, the impact of high levels of PEEP on right ventricular performance has been demonstrated in experimental and clinical models.
Dr. Demetrios Demetriades (Los Angeles, California): This is a good study with potentially important therapeutic implications. However, we must have in mind the study used very short-term outcomes-four hours.
We know that in ARDS nitric oxide improves temporary oxygenation but there is no improvement of outcomes. Why didn't you keep these animals alive for seven days? Thank you.
Dr. H. Gill Cryer (Los Angeles, California): First of all, I just want to applaud the authors because you were able to accomplish something that nobody else has done since we published that paper long ago. And it is old and so am I.
